Cutoff: 13 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
Consensus accurately retains the19-person open-label MDD result and identifies a masked caffeine-comparator result. The latter was independently verified in the original September2026 Donegan conference abstract, DOI10.1093/ijnp/pyag040.021, rather than accepted from synthesis. It reports primary MADRS nonsuperiority and active-arm masking; it is not a complete trial publication or definitive equivalence. The open-label positive remains exploratory, while the separately receipted clinical null narrows its causal attribution. Original PMID41202873. Access: abstract_metadata.
Consensus labels13/26micrograms as low doses. Original text explicitly states these are LSD tartrate equivalent to10/20micrograms base, fitting the registered base range. Original Methods use water placebo and a possible-drug-category cover story with end-session guesses; actual Results show no residual mood improvement. A26-number label alone cannot justify excluding this study, and a design label cannot guarantee successful masking. Original PMID35106880. Access: full_text_partial.
Consensus accurately distinguishes dose-day mood elevations from no baseline-to-six-week questionnaire/cognitive change in80healthy men. Four anxiety withdrawals are important. Baseline-expectancy-adjusted acute effects do not automatically control postdose recognition or establish diagnosed-MDD treatment. The same-trial sleep and PK reports are grouped rather than counted as independent clinical replication. Original PMID36997080. Access: abstract_metadata.
Consensus describes the self-blinding result as decisive on expectancy. Original Methods confirm participant-sourced uncontrolled substances/doses, randomized capsule schedules and forced guesses; Results show no accumulated benefit and loss of most acute/post-acute contrasts after guess adjustment. Recognition is a posttreatment variable and may carry genuine pharmacologic information, so this supports an expectancy alternative without proving all benefit is placebo. Original PMID33648632. Access: full_text_partial.
Consensus correctly reports baseline expectations predicting wellbeing gains in the prospective81-completer observational cohort. The exposure and expectancy were not randomized. The result informs competing models but neither proves exclusive placebo causation nor identifies an independent drug effect. Original PMID33479342. Access: abstract_metadata.
Consensus correctly reports a controlled psilocybin microdose symptom null and second-block blind breaking. The original duration is three weeks and drug differs fromLSD; this is an observed companion boundary, not a complete direct4–12weekLSD-MDD refutation. Baseline decreases in one block do not become between-arm efficacy. Original PMID34915762. Access: abstract_metadata.
Consensus emphasizes many microdosing nulls but its source coverage does not exhaust the selected2026 originals. The original pooled171-person truffle creativity report finds a restricted originality-quality positive surviving dose-guess adjustment. It is retained alongside effectively blinded cognitive/emotional null41110634; creativity is not sustained depression treatment and likely shared trials restrict independence. Original PMID41187880. Access: abstract_metadata.
The original ADHD trial adds clinically diagnosed six-week controlled evidence beyond the provider’s main healthy/MDD narrative. Actual Methods specify20micrograms base, on-site dosing and guesses; Results show no primary clinical superiority, with21/22active and16/24placebo guessing active after the last dose. Its secondary cognition report42322409 shares allocation. This marks an ADHD boundary without being relabeled anMDD result. Original PMID40105807. Access: full_text_partial.
Consensus appropriately separates full-dose and ketamine treatment. Actual COMP360 primary25mg contrast is positive at three weeks but sustained week-twelve response is not supportive; full-dose33852780 and41848690 have primary nulls despite secondary positives. These exact outcomes are more informative than a broad class efficacy claim and cannot establish low-doseLSD generalization. Original PMID36322843. Access: abstract_metadata.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.